A Novel, Non-Hallucinogenic Psychedelic for the Treatment of OCD and Tic Disorder
- Author: mycolabadmin
- 8/18/2025
- View Source
Summary
Researchers developed a new drug called HBL20017 based on psychedelic compounds that does not cause hallucinations. In animal tests, this drug significantly reduced obsessive behaviors and involuntary muscle twitches, suggesting it could treat conditions like obsessive-compulsive disorder and Tourette’s syndrome. A single dose showed beneficial effects that lasted up to 42 days, and the compound appeared safer than existing psychedelic treatments.
Background
A novel psychedelic-derived compound (HBL20017) with high functional efficacy at serotonin receptors (5-HT2A, 5-HT1A, 5-HT2C) has been designed. Previous research showed that psilocybin alleviates obsessive self-grooming in SAPAP3-/- mice, which model OCD and tic disorders in humans.
Objective
To determine the potential efficacy of HBL20017 in treating OCD and tic disorders by assessing its hallucinogenic properties, anti-obsessional potential, and safety profile.
Results
HBL20017 demonstrated high potency at serotonin receptors with no cytotoxicity or hERG inhibition. The compound did not induce HTR, suggesting non-hallucinogenic properties. A single dose significantly reduced marble burying and attenuated excessive self-grooming in SAPAP3-/- mice for up to 42 days, with effects appearing within 48 hours and alleviating head-body twitches.
Conclusion
HBL20017 is a non-hallucinogenic psychedelic with potential therapeutic applications for OCD and tic disorders, demonstrating favorable safety profiles and superior long-term efficacy compared to psilocybin in preclinical models.
- Published in:International Journal of Neuropsychopharmacology,
- Study Type:Preclinical Animal Study,
- Source: 10.1093/ijnp/pyaf052.019, PMC12359753